All results
27 results for weight and metabolic health study
-
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or…
- Ages
- 75 Years - N/A
- Sexes
- All
-
PPMI Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI)
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical…
- Ages
- 30 Years - N/A
- Sexes
- All
-
Sensitivity of Pharmacokinetics to Particle Size Distribution of Suspension-based Nasal Sprays
Currently FDA does not accept pharmacokinetic studies to show bioequivalence of locally-acting nasal suspension formulations. However, bioequivalence is…
- Ages
- 18 Years - 50 Years
- Sexes
- All
-
Immunotherapy for Patients With Advanced Kidney Cancer, The PDIGREE Study
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Effect of Armodafinil
Sleep deprivation slows reaction time, reduces vigilance and impairs judgment and information processing. Chronic effects include metabolic dysfunction,…
- Ages
- 18 Years - 35 Years
- Sexes
- All
-
NIH AIM 2 - Low Dose Pioglitazone in NASH
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…
- Ages
- 21 Years - 75 Years
- Sexes
- All
-
Genomic-Risk Stratified Txs for Unfavorable Intermediate Risk Prostate Cancer (Guidance)
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk)…
- Ages
- 18 Years - N/A
- Sexes
- Male